Sum­i­to­vant sub­sidiaries En­zy­vant and Al­ta­vant merge in­to com­bined com­pa­ny

Two Sum­i­to­vant Bio­phar­ma en­ti­ties are merg­ing un­der one name, ef­fec­tive im­me­di­ate­ly.

En­zy­vant Ther­a­peu­tics and Al­ta­vant Sci­ences an­nounced they have merged to form a sin­gu­lar en­ti­ty fo­cused on de­vel­op­ing ther­a­pies for pa­tients with rare dis­eases. The com­bined com­pa­ny will keep the name En­zy­vant and along with clin­i­cal de­vel­op­ment will even­tu­al­ly in­clude in-house man­u­fac­tur­ing.

Bill Symonds, the cur­rent CEO of both Al­ta­vant and En­zy­vant, is now CEO of the merged com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.